The use of bioregulatory peptides in the treatment of men with benign prostatic hyperplasia and chronic prostatitis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Benign prostatic hyperplasia (BPH), and chronic prostatitis (CP) are considered to be among the most common causes of lower urinary tract symptoms (LUTS) in men. The combination of BPH with CP raises many questions when choosing the right treatment strategy. For a long time, bioregulators isolated from the prostate gland of cattle have been successfully used in the treatment of CP. Objective: to evaluate the effectiveness of bioregulatory peptides, in particular vitaprost, in the treatment of men with benign prostatic hyperplasia and chronic prostatitis. Materials and methods. The study included 60 patients with BPH and CP, who were divided into two groups of 30 people. In the comparison group (CG), complex therapy with drugs from the group of alpha-blockers and fluoroquinolones was performed. In the main group (MG), a similar complex therapy was performed in combination with vitaprost tablets. The effectiveness of the treatment was evaluated after two weeks (visit 2) and after 4 weeks (visit 3). Results. In the MG, a more effective reduction in the severity of LUTs and manifestations of the inflammatory process was noted than in the HS. After 2 weeks of therapy in OG, the average score on the IPSS, QOL and NICH-CPSI questionnaires was lower by 2.4 points, 1.2 points and 2.5 points, respectively, the number of white blood cells in the prostate secret was on average 1.5 times less, and Qmax was higher by 1.4 ml/sec. The revealed differences were statistically significant (p<0.05). This trend continued after 4 weeks of therapy. Conclusion. Thus, the use of bioregulatory peptides, in particular the drug vitaprost, in patients with BPH and CP helps to reduce the severity of LUTs and pain in a shorter time, has a positive effect on the dynamics of the inflammatory process, which leads to an improvement in the quality of life of patients in this category.

Full Text

Restricted Access

About the authors

A. V Kuzmenko

Voronezh State Medical University n.a. N.N. Burdenko

Email: kuzmenkoav09@yandex.ru
MD, professor, Head of Department of Urology

Yu. Yu Vinnik

FGBOU VO “Krasnoyarsk State Medical University” named after professor V.F. Voyno-Yasenetsky of the Ministry of Health of Russia

Email: vinnik33@mail.ru
Ph.D., MD, professor at the Department of Urology, Andrology and Sexology IPO

V. V Kuzmenko

Voronezh State Medical University n.a. N.N. Burdenko

Email: kuzmenkovv2003@mail.ru
MD, professor at the Department of Urology

T. A Gyaurgiev

Voronezh State Medical University n.a. N.N. Burdenko

Email: tima001100@mail.ru
Ph.D., associate professor at the Department of Urology

References

  1. Урология. Российские клинические рекомендации. Под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. М.: ГЭОТАР-Медиа; 2018. 480 с.
  2. Gravas S., Cornu J.N., Drake M.J. et al. EAU guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). 2018. Available at: http://uroweb.org/guideline/treatment-of-non-neurogenic male-luts/ Accessed 5 May 2019
  3. Schaeffer A.J. Classification (Traditional and National Institutes of Health) and Demographics of Prostatitis/ Urology. 2002 Dec;60(6 Suppl):5-6; discussion 6-7. doi: 10.1016/s0090-4295(02)02292-6.
  4. Nickel J. Prostatitis. CUA Guidelines. Canadian Urol. Assoc. J. 2011;5(5):306- 315. https://www.ncbi.nlm.nih.gov/pubmed/22031609
  5. Rees J., Abrahams M., Doble A., Cooper A. and the Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int., 2015;116:509-525. 10.1111/bju.13101' target='_blank'>https://doi: 10.1111/bju.13101
  6. Roehrborn C.G., Barkin J., Tubaro A, Emberton M., Wilson T.H., Brotherton B.J., Castro R.P. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. BJU Int. 2014 Apr;113(4):623-635. doi: 10.1111/bju.12500.
  7. Roehrborn C.G., OyarzabalPerez I., Roos E.P., Calomfirescu N., Brotherton B., Wang F., Palacios J.M., Vasylyev A., Manyak M.J. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015;7. doi: 10.1111/bju.13033.
  8. Gupta N., Rogers T., Holland B., Helo S., Dynda D., McVary K.T. Three-Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial. J. Urol. 2018 Aug;200(2):405-413. doi: 10.1016/j.juro.2018.02.3088.
  9. Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Энтомологический препарат аденопросин в лечении пациентов с доброкачественной гиперплазией предстательной железы и хроническим простатитом. Урология. 2021;1:39-44
  10. Kudryavtsev Yu.V., Sivkov A.V. Morphological changes in prostate tissue in benign hyperplasia. Experimental and clinical urology. 2010;1:18-22.
  11. Bartoletti R., Cai T, Mondaini N, Dinelli N, Pinzi N, Pavone C. et al. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multi-center case-control observational study. J. Urol. 2007;178:11-15. https://www.ncbi.nlm.nih.gov/pubmed/17937946
  12. Krsmanovic A., Tripp D., Nickel J. et al. Psychosocial mechanisms of the pain and quality of life relationship for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Canadian Urological Association Journal, 2014; 8 (11-12):403-408. 10.5489/cuaj.2179' target='_blank'>https://doi: 10.5489/cuaj.2179
  13. Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А., Баранников И.И. Хронобиологический статус больных с хроническим простатитом на фоне аденомы простаты. Системный анализ и управление в биомедицинских системах. 2017;16(3):513-516
  14. Hu C., Yang H., Zhao Y. et al. The role of inflammatory cytokines and ERK1/2 signaling in chronic prostatitis/chronic pelvic pain syndrome with related mental health disorders. Sci. Rep., 2016;6:28608. https://www.ncbi.nlm.nih.gov/pubmed/27334333
  15. Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Комбинированная медикаментозная терапия больных ДГПЖ. Урология. 2018; 1:101-105
  16. Huang T., Li W., Peng B. Correlation of inflammatory mediators in prostatic secretion with chronic prostatitis and chronic pelvic pain syndrome. Andrologia. 2017;e12860. https://doi.org/10.1111/and12860
  17. Кузьменко А.В., Кузьменко В.В., Гяургиев ТА. Эффективность применения фезотеродина у больных после трансуретральной резекции простаты. Урология. 2019;1:52-55
  18. Кузьменко А.В., Кузьменко В.В., Гяургиев ТА. Эффективность макролидов в лечении пацинетов с урогенитальными инфециями. РМЖ. 2019;27(10):46-49
  19. Аляев Ю.Г., Гаджиева З.К., Рапопорт Л.М., Казилов Ю.Б. Медикаментозное лечение симптомов нижних мочевых путей у мужчин. Роль уроселективности в выборе препарата. Андрология и генитальная хирургия. 2014;1:6-14
  20. Гаджиева З.К., Казилов Ю.Б. Новые возможности лечения комбинированных симптомов нижних мочевыводящих путей у пациентов с доброкачественной гиперплазией предстательной железы - предпосылки и преимущества. Урология. 2017;1:95-102
  21. Морозов В.Г., Хавинсон В.Х. Новый класс биологических регуляторов многоклеточных систем - цитомедины. Успехи совр. биологии. 1983;96(6):339-352
  22. Аль-Шукри С.Х., Кузьмин И.В., Горбачев А.Г. Простатические пептидные биорегуляторы в лечении урологических болезней. Пособие для врачей. СПб., 2011
  23. Кузьмин И.В. Витапрост форте в лечении больных доброкачественной гиперплазией предстательной железы: патогенетические основы и клинические результаты. Урология. 2019;4:141-147
  24. Ткачук В.Н., Ткачук И.Н. Эффективность витапроста у больных хроническим простатитом. Урология. 2012;4:88-91
  25. Лопаткин Н.А., Камалов А.А., Мазо Е.Б., Охотобов Д.А. Применение таблеток препарата Витапроста для профилактики обострений хронического абактериального простатита. Урология. 2009;1:29-35

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies